Auxillium, Stendra has already grabbed a 5% share of Viagra & Cialis market. That translates to about $150 million in annual sales.
STENDRA U.S. net revenues of $9.3 million – initial product launch momentum is positive with STENDRA gaining an 8.0 percent share of all new PDE5 prescriptions and a 4.2 percent share of total PDE5 prescriptions amongst Auxilium's target physician population, those doctors responsible for approximately 45 percent of all PDE5 prescriptions. In the third quarter, Auxilium also increased the number of physicians prescribing STENDRA by 45 percent over the second quarter of 2014 to 16,430 and the productivity per target prescriber, with 12.3 prescriptions written to date per physician
And then drop Dollar and by then GOLD is already ordered by Central Bank and depreciate bond yield to Zero and China start selling US Treasury bond and throw away price and reduce debt from 18 Trillions to few Trillions....
oster sessions on STENDRA will include new analyses from the study that supported the updated labeling recommendation indicating that STENDRA can be taken as early as approximately 15 minutes before sexual activity.
Data to be presented on XIAFLEX for Peyronie's disease include:
Changes in the Effects of Peyronie's Disease After Treatment with Collagenase Clostridium Histolyticum According to Men with Peyronie's Disease and their Female Partners: Moderated Posters 4: Peyronie's disease, Friday, November 21, 5:15 p.m. ET
Peyronie's Disease Symptom Bother Reduction is Related to Penile Curvature Improvement in Response to Treatment with Collagenase Clostridium Histolyticum: Results From Two Large Double-Blind Randomized, Placebo Controlled Phase 3 Studies: Moderated Posters 4: Peyronie's disease, Friday, November 21, 5:15 p.m. ET
Meaningful Change in Peyronie's Disease Following Treatment with Collagenase Clostridium Histolyticum: Results From Two Large Double-Blind Randomized, Placebo Controlled Phase 3 Studies: Moderated Posters 4: Peyronie's disease, Friday, November 21, 5:15 p.m. ET
Relationship of Factors Associated with Peyronie's Disease (PD) that Affect PD Bother and Erectile Function: Unmoderated Posters 4: Peyronie's disease
Outcomes Associated with Collagenase Treatment of Peyronie's Disease by Duration of Disease: Unmoderated Posters 4: Peyronie's disease
Data to be presented on STENDRA for erectile dysfunction include:
The Efficacy of Avanafil in Subjects with Intercourse Attempts Within 15 Minutes After Dosing: Moderated Posters 5: ED Diagnosis & Medical Treatment, Saturday, November 22, 11:10 a.m. ET
Successful Intercourse in Men with Erectile Dysfunction Within the first Three doses of Avanafil: Moderated Posters 5: ED Diagnosis & Medical Treatment, Saturday, November 22, 11:10 a.m. ET
Can this volume dictate the price? or its scaring tactics ...!!
Yamana Gold Inc (NYSE:AUY)
Tangible Book Value Per Share
$7.62 (As of Sep. 2014)
Tangible book value per share is calculated as the total tangible equity divided by Shares Outstanding. Total tangible equity is calculated as the total equity minus preferred stock minus intangibles. Yamana Gold Inc's tangible book value per share for the quarter that ended in Sep. 2014 was $7.62.
Since intangibles such as goodwill cannot be sold when the company liquidates, tangible book value per share is considered more accurate in reflecting how much shareholders will receive when the company liquidates.
Beijing has made no secret of its desire to diversify from greenback assets -- mainly U.S. Treasuries -- and for the establishment of another reserve currency to use as a store of wealth and for international transactions. The European sovereign debt crisis has reduced the allure of the euro for those purposes. While Beijing has voiced limited support for the various schemes to ease Europe's woes, it has added to its holdings of other, smaller currencies, such as the Australian dollar.
But more recent Treasury data show China has been selling Treasuries outright. And while the markets have been complacent to the point of snarkiness, MacroMavens' Stephanie Pomboy thinks that's wrong. Unlike other Cassandras, she's been right in her warnings -- notably in the middle of the last decade that the U.S. financial system was dangerously exposed to a bubble in U.S. real estate. Hers was a lonely voice then because everybody knew, of course, house prices always rose.
As for the present conundrum, there's an $800 billion gap between the $1.1 trillion the Treasury is borrowing to cover the budget gap and the roughly $300 billion overseas investors are buying, Pomboy calculates. Banks, corporations and households have been doing little to fill that gap, preferring higher-yielding securities, so "it would appear the heavy lifting has been done by long-only bond managers extending duration and specs rushing to cover their shorts," she writes.
But Pomboy has little doubt that the Fed will step in to fill the gap left by others. In other words, debt monetization, a fancy term for printing money to cover the government's debts, which in polite circles these days is called "quantitative easing."
"Having pushed interest rates to zero, launched QE1 and QE2, there's no reason to believe that the Fed is going to allow free-market forces to destroy the fragile recovery it has worked so hard to coax forth now. And make no mistake, at $800 billion, allowing the markets to resolve the shortfall in demand would send rates to levels that would absolutely quash this recovery…if not send the economy in a real depression."
But her real concern is a bigger one. "The Fed's 'need' to take on an even more active role as foreigners further slow the purchases of our paper is to put the pedal to the metal on the currency debasement race now being run in the developed world -- a race which is speeding us all toward the end of the present currency regime." That is, the dollar-centric, floating exchange-rate system of the past four decades since the end of Bretton Woods system, when the dollar's convertibility into gold was terminated.
OXGN - have licensed Contrave North American rights to Takeda Pharmaceuticals. received $50.0 million from Takeda at the inception of our collaboration, and to receive additional payments of over $1.0 billion upon achieving certain milestones, including $100.0 million paid on approval and the first commercial sale of Contrave in the United States. and Takeda will share post approval clinical development expenses.
Rest of World Rights
Orexigen retains all rights to naltrexone SR/bupropion SR outside North America and is seeking a partner to support rest of world development and commercialization.
Empatic™: Global Rights
Orexigen owns global rights to Empatic and is seeking a partner for Empatic development and commercialization.
You know why Jay joined OREXIGEN ?
Jay spent ten years at Amgen Inc. where he served in various senior business development roles, including founder and Managing Director of Amgen Ventures, and earlier as head of Corporate Development. His track record includes such notable completed transactions as the acquisitions of Immunex and Tularik as well as numerous other business development efforts totaling over $15 billion in value. Before joining Amgen, Jay spent five years in the bioengineering labs at Genzyme
Jay was a Partner at Groundswell Advisors, a biotechnology consulting firm, providing guidance and operational execution in corporate strategy, commercialization, financing and partnership opportunities. While at Groundswell Advisors, he served as acting chief executive officer of Unity Pharma, consulted to numerous small biotech companies, and served on the board of directors of Seredigm Corp. Prior to establishing Groundswell, Jay spent ten years at Amgen Inc. where he served in various senior business development roles, including founder and Managing Director of Amgen Ventures, and earlier as head of Corporate Development. His track record includes such notable completed transactions as the acquisitions of Immunex and Tularik as well as numerous other business development efforts totaling over $15 billion in value. Before joining Amgen, Jay spent five years in the bioengineering labs at Genzyme and Advanced Tissue Sciences.
Because AMGEN is buying OREXIGEN shortly..
Mr. Narachi retired as an officer and Vice President of Amgen Inc., a leading therapeutics company, where he served as General Manager of Amgen's Anemia Business from 1999 to 2003. Mr. Narachi joined Amgen in 1984 and held various positions throughout the organization including: Product Development Team Leader for NEUPOGEN® Director of Clinical Operations in Thousand Oaks, CA and Cambridge, UK; Vice President of Development and Representative Director for Amgen Japan; Head of Corporate Strategic Planning; Chief Operations Officer of Amgen BioPharma; and Vice President, Licensing and Business Development. He currently serves on the board of directors of Celladon Corporation, a publicly traded biotechnology company.